EN DE
STOCK COMPARISON

AnnJi Pharmaceutical Co. vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how AnnJi Pharmaceutical Co. (7754) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees AnnJi Pharmaceutical Co. as the less overvalued of the two: AnnJi Pharmaceutical Co. trades at TWD 54.80 versus a fair value of TWD 32.05 (-42%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
AnnJi Pharmaceutical Co.
7754.TWO · TWD · Healthcare
-42%
upside to fair value
overvalued
PriceTWD 54.80
Fair ValueTWD 32.05
Quality36/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

AnnJi Pharmaceutical Co.Vertex Pharmaceuticals
Valuation
P/E (TTM)28.8×
23.82×P/S (TTM)10.06×
0.56×P/B6.59×
EV/EBITDA23.8×
PEG1.72×
Profitability
0%Net margin36%
Operating margin38%
-73%Return on equity24%
-29%Return on assets12%
Growth
-98%Revenue growth (YoY)8%
66.8%Avg. growth/yr (3Y)10.6%
Avg. growth/yr (5Y)14.2%
Balance & size
Debt / equity0.03×
$180MMarket cap$123B
expensiveGrowth qualityhealthy

Vertex Pharmaceuticals leads: 2 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

AnnJi Pharmaceutical Co.of which business quality 36 · market factors 53 Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
0
72
Quality GrowthAre margins and returns improving?
22
65
CashflowEarnings quality: real cash, not paper profit
11
79
Fin. StrengthBalance sheet, leverage, solvency risk
95
92
InvestmentDisciplined investing over empire-building
62
58
Low VolatilityCalm price path (market factor)
72
86
MomentumPrice trend over the last 3–12 months (market factor)
44
54
52W MomentumDistance to the 52-week high (market factor)
47
59
Net IssuanceBuybacks instead of dilution
30
82

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

AnnJi Pharmaceutical Co.

Asset-BasedTWD 32.05

1 of 1 models see the stock below the current price.

Vertex Pharmaceuticals

DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692

18 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

AnnJi Pharmaceutical Co.
Bear TWD 21.05Fair Value TWD 32.05Bull TWD 39.82
TWD 54.80 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

AnnJi Pharmaceutical Co. · Healthcare

Quality score36 · bottom 25%
Fair value upside-42% · below median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-44% · below median

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees AnnJi Pharmaceutical Co. as the less overvalued of the two: AnnJi Pharmaceutical Co. trades at TWD 54.80 versus a fair value of TWD 32.05 (-42%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.